The potential of antibody-drug conjugates in immunotherapy for non-small cell lung cancer: current progress and future
{{output}}
Antibody-drug conjugates (ADCs) have gained significant attention as a promising therapeutic strategy for non-small cell lung cancer (NSCLC), combining the precision of monoclonal antibodies with the potent cytotoxic effects of chemotherapy. This review summar... ...
